{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:22:48Z","timestamp":1794601368555,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41591-026-04679-x","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:03:27Z","timestamp":1790067807000},"page":"4127-4135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b\/2 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-5096","authenticated-orcid":false,"given":"Choong-kun","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"given":"Taek","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Il Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1357-7015","authenticated-orcid":false,"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5486-9818","authenticated-orcid":false,"given":"Se Jun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Kyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junghun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changhoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9913-8883","authenticated-orcid":false,"given":"Dong-Hoe","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sora","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1833-6576","authenticated-orcid":false,"given":"Minsuk","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-8937","authenticated-orcid":false,"given":"Beodeul","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sejung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woochan","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Ho","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Gon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"4679_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","volume":"23","author":"JM Banales","year":"2026","unstructured":"Banales, J. M. et al. Cholangiocarcinoma 2026: status quo, unmet needs and priorities. Nat. Rev. Gastroenterol. Hepatol. 23, 65\u201396 (2026).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"4679_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00398-y","volume":"8","author":"JC Roa","year":"2022","unstructured":"Roa, J. C. et al. Gallbladder cancer. Nat. Rev. Dis. Primers 8, 69 (2022).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"4679_CR3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","volume":"4","author":"M Ueno","year":"2019","unstructured":"Ueno, M. et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol. Hepatol. 4, 611\u2013621 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"4679_CR4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","volume":"6","author":"RD Kim","year":"2020","unstructured":"Kim, R. D. et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 6, 888\u2013894 (2020).","journal-title":"JAMA Oncol."},{"key":"4679_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh, D. Y. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1, EVIDoa2200015 (2022).","journal-title":"NEJM Evid."},{"key":"4679_CR6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1853\u20131865 (2023).","journal-title":"Lancet"},{"key":"4679_CR7","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1634\/theoncologist.2019-0922","volume":"25","author":"C Vivaldi","year":"2020","unstructured":"Vivaldi, C. et al. HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer. Oncologist 25, 886\u2013893 (2020).","journal-title":"Oncologist"},{"key":"4679_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.humpath.2020.08.006","volume":"105","author":"N Hiraoka","year":"2020","unstructured":"Hiraoka, N. et al. Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer. Hum. Pathol. 105, 9\u201319 (2020).","journal-title":"Hum. Pathol."},{"key":"4679_CR9","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.4143\/crt.2022.1450","volume":"55","author":"SH Lee","year":"2023","unstructured":"Lee, S. H. et al. ARID1A mutation from targeted next-generation sequencing predicts primary resistance to gemcitabine and cisplatin chemotherapy in advanced biliary tract cancer. Cancer Res. Treat. 55, 1291\u20131302 (2023).","journal-title":"Cancer Res. Treat."},{"key":"4679_CR10","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1158\/1078-0432.CCR-25-2153","volume":"32","author":"SS Lee","year":"2026","unstructured":"Lee, S. S. et al. HER2-positivity as a prognostic biomarker and therapeutic target in advanced biliary tract cancer: a multi-institutional analysis. Clin. Cancer Res. 32, 1745\u20131754 (2026).","journal-title":"Clin. Cancer Res."},{"key":"4679_CR11","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle, M. et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 22, 1290\u20131300 (2021).","journal-title":"Lancet Oncol."},{"key":"4679_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","volume":"8","author":"CK Lee","year":"2023","unstructured":"Lee, C. K. et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). Lancet Gastroenterol. Hepatol. 8, 56\u201365 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"4679_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","volume":"24","author":"JJ Harding","year":"2023","unstructured":"Harding, J. J. et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 24, 772\u2013782 (2023).","journal-title":"Lancet Oncol."},{"key":"4679_CR14","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1200\/JCO.23.00606","volume":"41","author":"Y Nakamura","year":"2023","unstructured":"Nakamura, Y. et al. Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study. J. Clin. Oncol. 41, 5569\u20135578 (2023).","journal-title":"J. Clin. Oncol."},{"key":"4679_CR15","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1200\/JCO.23.02010","volume":"42","author":"A Ohba","year":"2024","unstructured":"Ohba, A. et al. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial. J. Clin. Oncol. 42, 3207\u20133217 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4679_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac4925","volume":"7","author":"P Muller","year":"2015","unstructured":"Muller, P. et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade. Sci. Transl. Med. 7, 315ra188 (2015).","journal-title":"Sci. Transl. Med."},{"key":"4679_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2018.05.009","volume":"430","author":"BKR Chaganty","year":"2018","unstructured":"Chaganty, B. K. R. et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN\u03b3 secretion. Cancer Lett. 430, 47\u201356 (2018).","journal-title":"Cancer Lett."},{"key":"4679_CR18","first-page":"2244","volume":"62","author":"CM zum Buschenfelde","year":"2002","unstructured":"zum Buschenfelde, C. M., Hermann, C., Schmidt, B., Peschel, C. & Bernhard, H. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 62, 2244\u20132247 (2002).","journal-title":"Cancer Res."},{"key":"4679_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ccr.2010.06.014","volume":"18","author":"S Park","year":"2010","unstructured":"Park, S. et al. The therapeutic effect of anti-HER2\/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18, 160\u2013170 (2010).","journal-title":"Cancer Cell"},{"key":"4679_CR20","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.1073\/pnas.1016569108","volume":"108","author":"J Stagg","year":"2011","unstructured":"Stagg, J. et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108, 7142\u20137147 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4679_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1512942","volume":"8","author":"T Triulzi","year":"2019","unstructured":"Triulzi, T. et al. HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. Oncoimmunology 8, e1512942 (2019).","journal-title":"Oncoimmunology"},{"key":"4679_CR22","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1\u03b2-dependent adaptive immunity against tumors. Nat. Med. 15, 1170\u20131178 (2009).","journal-title":"Nat. Med."},{"key":"4679_CR23","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1056\/NEJMc2408121","volume":"391","author":"YY Janjigian","year":"2024","unstructured":"Janjigian, Y. Y. et al. Pembrolizumab in HER2-positive gastric cancer. N. Engl. J. Med. 391, 1360\u20131362 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4679_CR24","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1158\/1078-0432.CCR-24-1265","volume":"30","author":"YH Bang","year":"2024","unstructured":"Bang, Y. H. et al. Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a potential biomarker for immune checkpoint inhibitors in patients with biliary tract cancer. Clin. Cancer Res. 30, 4635\u20134643 (2024).","journal-title":"Clin. Cancer Res."},{"key":"4679_CR25","doi-asserted-by":"publisher","first-page":"e2500510","DOI":"10.1200\/PO-25-00510","volume":"9","author":"H Kim","year":"2025","unstructured":"Kim, H. et al. Artificial intelligence-powered human epidermal growth factor receptor 2 quantification and clinical outcomes in human epidermal growth factor receptor 2-positive biliary tract cancer treated with trastuzumab plus folinic acid, fluorouracil, and oxaliplatin. JCO Precis. Oncol. 9, e2500510 (2025).","journal-title":"JCO Precis. Oncol."},{"key":"4679_CR26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","volume":"35","author":"AN Bartley","year":"2017","unstructured":"Bartley, A. N. et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J. Clin. Oncol. 35, 446\u2013464 (2017).","journal-title":"J. Clin. Oncol."},{"key":"4679_CR27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1200\/JCO.23.01193","volume":"42","author":"V Ostwal","year":"2024","unstructured":"Ostwal, V. et al. Trastuzumab plus gemcitabine\u2013cisplatin for treatment-naive human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB). J. Clin. Oncol. 42, 800\u2013807 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4679_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33267-z","volume":"13","author":"CK Lee","year":"2022","unstructured":"Lee, C. K. et al. A single arm phase Ib\/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Nat. Commun. 13, 6002 (2022).","journal-title":"Nat. Commun."},{"key":"4679_CR29","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.2217\/fon-2022-0595","volume":"18","author":"J Tabernero","year":"2022","unstructured":"Tabernero, J. et al. HERIZON-GEA-01: zanidatamab\u2009+\u2009chemo\u2009\u00b1\u2009tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 18, 3255\u20133266 (2022).","journal-title":"Future Oncol."},{"key":"4679_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. 42, 47\u201358 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4679_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamaoncol.2025.4736","volume":"12","author":"S Pant","year":"2026","unstructured":"Pant, S. et al. Zanidatamab in HER2-positive metastatic biliary tract cancer: final results from HERIZON-BTC-01. JAMA Oncol. 12, 106\u2013109 (2026).","journal-title":"JAMA Oncol."},{"key":"4679_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"4679_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01018-0","volume":"8","author":"CY Ock","year":"2017","unstructured":"Ock, C. Y. et al. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat. Commun. 8, 1050 (2017).","journal-title":"Nat. Commun."},{"key":"4679_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-025-03834-x","volume":"23","author":"S Mii","year":"2025","unstructured":"Mii, S. et al. Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab. World J. Surg. Oncol. 23, 258 (2025).","journal-title":"World J. Surg. Oncol."},{"key":"4679_CR35","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143\u2013e152 (2017).","journal-title":"Lancet Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04679-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04679-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04679-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T19:49:13Z","timestamp":1794599353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04679-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4679"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04679-x","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C-k.L. has received honoraria from Astellas Pharma, AstraZeneca, Celgene\/Bristol-Myers Squibb, Ono Pharmaceutical, Servier, Boryung Corporation and Yuhan, consulting fees from AstraZeneca, Servier, MSD, Roche and Daiichi Sankyo and research grants or support from Ono Pharmaceuticals, GC Biopharma, Idience, Selecxine and Boryung (outside the submitted work). H.J. Chon has received honoraria from Eisai, Roche, ONO, MSD, BMS, BeOne, Sanofi, Servier, AstraZeneca, Aptamer Science and Boryung, served on advisory boards for Eisai, Roche, ONO, MSD, BMS, BeOne, Servier, AstraZeneca, Boryung, IMBDx and Aptamer Science and received research grants from Roche, BeOne, Medivir, Servier, Guardant Health, IMBDx, Dong-A ST and Boryung Pharmaceuticals. Jin Won Kim has received a research grant from Boryung and consulting fees from AstraZeneca, Beyond Bio, Eisai, MSD, BeiGene, Celgene\/Bristol-Myers Squibb, GC Cell, Ono Pharmaceuticals, Sanofi-Aventis, Servier and TCUBEit. C.Y. has received honoraria from AstraZeneca, MSD, Servier, Eisai, Roche, Bristol-Myers Squibb, Ipsen, Novartis, Boryung, Qurient, HLB, ABL Bio, CKD Pharm, Abbisko and Elevar Therapeutics and research grants from AstraZeneca, Ipsen, Servier, Boryung, Lunit and Boehringer Ingelheim. M.K. has received honoraria from MSD, AstraZeneca, Bristol-Myers Squibb Korea and Astellas Pharma, served in a consulting or advisory role for Eisai and received research funding from AstraZeneca. W.H. is an employee of Lunit. C.H.A. is an employee and stockholder of Lunit. C.G.K. has served consulting or advisory roles for Astellas, Amgen, BeOne, Johnson & Johnson\/Janssen, MSD Oncology, Novartis, Ono Pharmaceutical and Pfizer, received speaker\u2019s bureau from Astellas, AstraZeneca, BeOne, Dong-A ST, Hanmi, Merck, MSD Oncology and Novartis and received research funding from Astellas, Exelixis and Ipsen. H.J. Choi has served consulting or advisory roles for AstraZeneca, Roche and BeOne Medicine. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}